Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)

University Hospital, Tours69 enrolled

Overview

Adalimumab is a fully human monoclonal antibody to tumor necrosis factor-alpha (TNF-α) approved in rheumatoid arthritis (RA) refractory to disease modifying anti rheumatic drugs (DMARDs) and for the treatment of severe, active and progressive RA in adults not previously treated with methotrexate. However, almost one third of patients have no response and approximately 15% develop antibodies towards adalimumab (ATA) after a 6 month course of treatment. There is a relationship between adalimumab concentration and clinical response obtained after 6 month of treatment. Furthermore adalimumab concentration measured 3 months after initiation seems to predict the clinical response at 6 months. There is an important inter individual pharmacokinetic variability of adalimumab. Side effects may occur at the recommended dose and more than 3 months of treatment are generally required to estimate the clinical response. A therapeutic drug monitoring could help clinicians to early adjust the dose to optimize the response and to avoid dose related side effects. To date there is no definite adalimumab target concentration predictive of the clinical response to allow such a pharmacologic monitoring.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Rheumatoid Arthritis

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * RA according to the American College of Rheumatology (ACR) 1987 criteria * Treatment with Adalimumab has been chosen by the physician / patient * Treatment given in accordance to the SPC * Stable Disease modifying anti rheumatic drugs (DMARDs) and glucocorticoids 4 weeks before enrollment and during the study period. * Signed consent Exclusion Criteria: * more than one previous treatment with anti TNF-alpha * Past history of malignancy, AIDS * Pregnancy * Change in DMARDS or glucocorticoid dose 4 weeks before entering the study * Active or latent tuberculosis, other active infections * Surgery scheduled during the study period

Locations (7)

CHRU de Brest

Brest, France

CHR du Mans

Le Mans, France

CHRU de Nantes

Nantes, France

CHR d'Orléans

Orléans, France

CHRU de Poitiers

Poitiers, France

CHRU de Rennes

Rennes, France

CHRU de Tours

Tours, France

Outcomes

Primary Outcomes

To characterize the concentration-effect relationship of adalimumab in rheumatoid arthritis

The primary objective is to characterize the concentration-effect relationship of adalimumab in rheumatoid arthritis (RA). To this aim, adalimumab concentration on the one hand and clinical and biological markers of disease activity on the other hand will be measured at baseline, week 4, week 8, week 12 and at week 26. Pharmacodynamic (PD) parameters will be estimated using PK(pharmacokinetic)-PD models in which Emax (maximum effect) and EC50 (concentration at which the effect is 50% of the maximum) will describe adalimumab effect on each markers of response.

Time frame: During the 26 weeks of follow up.

Secondary Outcomes

To study the relationship between genetic factors, immunogenicity and response to adalimumab in rheumatoid arthritis

The secondary endpoints consist on the association study between FCGR3A polymorphisms, transcriptomic analysis (at baseline), presence of antibodies toward adalimumab (ATA) on the one hand and estimited individuals pharmacodynamic parameters on the other hand. Measurements will be carried out at baseline, week 4, week 8, week 12 and at week 26.

Time frame: During the 26 weeks of follow up.